Long-Term Disease Control After locoregional Pelvic Chemoradiation in Patients with Advanced Anal Squamous Cell Carcinoma.
Fiche publication
Date publication
juillet 2022
Journal
Frontiers in oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BORG Christophe, Dr VIENOT Angélique, Dr KIM Stephano, Dr BOUSTANI Jihane
Tous les auteurs :
Grave A, Blanc J, De Bari B, Pernot M, Boulbair F, Noirclerc M, Vienot A, Kim S, Borg C, Boustani J
Lien Pubmed
Résumé
The incidence of metastatic squamous cell carcinoma of the anus (SCCA) is increasing. Even if systemic docetaxel, cisplatin, and 5-Fluorouracil (DCF) provide a high rate of long-term remission, the role of pelvic chemoradiation (CRT) is unknown in this setting. We reported the safety and efficacy of local CRT in patients with synchronous metastatic SCCA who achieved objective response after upfront DCF.
Mots clés
long-term control, metastatic setting, pelvic chemoradiotherapy, squamous cell carcinoma of the anus (SCCA), upfront chemotherapy
Référence
Front Oncol. 2022 07 22;12:918271